Innovus Pharmaceuticals Inc. (fka INNV)

[gi197845]

Dr.Damaj over promised and under delivered. I guess it's good that Q1 2017 was better than Q1 2016, but geeze the operating expenses keep going up and the dilution and the slow and corrupted FDA. INNV has so many people to pay (including Damaj himself) that even if he could get fluticare to market in July, would there even be enough margin left for any profit? One article said fluticare would be fast tracked and now it won't be sold until December 2017? How is that fast tracked? Why bother with a backdoor way to sell Fluticare sooner when the FDA has until 12/31/17 to approve the original fluticare ANDA? It's amazing how this was hyped and went to .66 and now the hype is out of this balloon, much like a used condom.